Paramount Bed Holdings 7817.T Holds ¥3,515 as Healthcare Sector Stabilizes

Paramount Bed Holdings Co., Ltd. (7817.T) trades flat at ¥3,515 on the JPX in pre-market activity, reflecting steady demand for medical care equipment across Japan’s aging healthcare sector. The Tokyo-based manufacturer of hospital and nursing care beds maintains a market cap of ¥197.1 billion, serving 41,260 employees worldwide. With a B+ grade from Meyka AI and a 3.16% dividend yield, the stock appeals to income-focused investors seeking exposure to Japan’s defensive healthcare segment. The company’s solid balance sheet and consistent earnings support its position as a leader in medical instruments and supplies.

7817.T Stock Performance and Technical Position

Paramount Bed Holdings trades at ¥3,515 with zero daily movement, sitting between its day low of ¥3,510 and day high of ¥3,515. Volume reached 370,600 shares, exceeding the 179,021-share average by 107%, signaling renewed investor interest. The stock trades above its 50-day average of ¥1,126,605,950 and 200-day average of ¥281,653,632, confirming a strong uptrend structure.

Year-to-date, 7817.T has climbed 0.29%, while the six-month gain stands at 30.62%. Over the past year, the stock surged 31.99%, demonstrating resilience through market cycles. The 52-week range spans ¥2,120 to ¥56.33 billion, with the current price near mid-cycle levels. This stability reflects consistent demand for medical care solutions in Japan’s aging population.

Financial Metrics and Valuation

Paramount Bed Holdings trades at a PE ratio of 21.46, slightly elevated but justified by healthcare sector growth. The price-to-book ratio stands at 1.44, indicating fair valuation relative to tangible assets. Earnings per share reached ¥163.76, while revenue per share totaled ¥1,908.41, demonstrating solid operational performance.

The company maintains a fortress balance sheet with a current ratio of 3.85, well above the 2.0 safety threshold. Debt-to-equity sits at just 0.055, among the lowest in the medical supplies industry. Return on equity of 6.74% and return on assets of 5.08% show efficient capital deployment. Cash per share of ¥770.33 provides ample liquidity for dividends and strategic investments. Track 7817.T on Meyka for real-time updates on these key metrics.

Meyka AI Grade and Investment Outlook

Meyka AI rates 7817.T with a grade of B+, reflecting strong fundamentals across multiple dimensions. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating recommendation is Buy, supported by strong DCF and ROA scores of 4 each, indicating undervaluation and efficient asset use.

The company’s dividend yield of 3.16% attracts income investors seeking stable returns. Dividend per share reached ¥111, growing 32.98% year-over-year. Operating cash flow growth of 38.94% and free cash flow growth of 146.04% signal improving cash generation. These grades are not guaranteed and we are not financial advisors. The combination of defensive healthcare exposure and attractive income makes 7817.T suitable for conservative portfolios.

Paramount Bed Holdings Co., Ltd. Price Forecast

Meyka AI’s forecast model projects 7817.T reaching ¥3,224.38 over the next 12 months, implying -8.27% downside from current levels. However, the three-year forecast climbs to ¥3,589.85, representing 2.13% upside, suggesting a recovery phase. The five-year target of ¥3,956.03 indicates 12.54% total appreciation, while the seven-year forecast reaches ¥4,300.96, or 22.35% gains.

These projections reflect Meyka AI’s analysis of sector tailwinds, demographic trends, and company fundamentals. The near-term consolidation aligns with broader healthcare sector weakness, while long-term forecasts capture Japan’s aging population driving sustained demand for medical care beds and equipment. Investors with multi-year horizons may view current levels as accumulation opportunities.

Final Thoughts

Paramount Bed Holdings (7817.T) remains a stable healthcare play trading at ¥3,515 with strong fundamentals and a B+ Meyka AI grade. The company’s fortress balance sheet, 3.16% dividend yield, and exposure to Japan’s aging demographic support long-term value creation. While near-term forecasts suggest modest downside, the five-to-seven-year outlook points to meaningful appreciation as healthcare demand accelerates. Conservative investors seeking defensive exposure with income should monitor 7817.T for entry opportunities during market weakness.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.